Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence

By sjmartinez • January 25, 2025

Krishnan S, Srivastava PK, Attaluri J, Nayeri R, Chatterjee D, Patel J, Nsair A, Budoff M, Nayeri A. Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence. J Cardiovasc Dev Dis. 2025 Jan 7;12(1):19. doi: 10.3390/jcdd12010019. PMID: 39852297; PMCID: PMC11766028.

Tags: Cardiology/Epi, GIP GLP-1 receptor agonist, Harbor UCLA, Hematology/Oncology, Metabolic syndrome, Obesity, Publications, semaglutide, tirzepatide, Veterans Administration, weight loss

Related Posts

Heart Failure Quality of Care Among Asian Patients in the United States

Huang X, Huffman MD, Kandula NR, Petito LC, Agarwal A, Yancy CW, Fonarow GC, Jhund PS, Mefford MT, Reynolds KL, Khan SS, Shah NS. Heart[...]

Public Reporting of Quality and Clinical Outcomes in the Get With The Guidelines-Stroke Registry

Mullen MT, Zhao J, Jiang T, Gao Z, Buechner J, Wahab F, Seo MH, Harder B, Schwamm LH, Fonarow GC, Smith EE, Xian Y, Messé[...]

Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and altered bile pathway gene expression

Zhao X, Zhou J, Chyu KY, Erbay E, Cercek B, Shah PK, Dimayuga PC. Myeloid Fmr1 deficiency in mice results in reduced serum cholesterol and[...]